ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
Beam Therapeutics Inc

Beam Therapeutics Inc (BEAM)

24.92
0.12
( 0.48% )
更新日時: 01:17:11

個人投資家向けのプロ仕様のツール。

主要統計と詳細

通貨
24.92
買値
24.89
売値
24.96
出来高
292,966
24.1805 日の範囲 24.985
20.84 52 週間の範囲 49.50
時価総額
前日終値
24.80
始値
24.82
最終取引時間
01:17:25
財務取引量
US$ 7,252,557
VWAP
24.7556
平均取引量 (3 か月)
1,164,511
発行済株式数
82,805,627
配当利回り
-
PER
-15.50
1 株当たり利益 (EPS)
-1.6
歳入
377.71M
純利益
-132.53M

Beam Therapeutics Inc について

Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio co... Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. 詳細を表示

セクター
Biological Pds,ex Diagnstics
業界
Biological Pds,ex Diagnstics
ウェブサイト
本社
Wilmington, Delaware, USA
設立
-
Beam Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the ナスダック市場 with ticker BEAM. The last closing price for Beam Therapeutics was US$24.80. Over the last year, Beam Therapeutics shares have traded in a share price range of US$ 20.84 to US$ 49.50.

Beam Therapeutics currently has 82,805,627 shares in issue. The market capitalisation of Beam Therapeutics is US$2.05 billion. Beam Therapeutics has a price to earnings ratio (PE ratio) of -15.50.

BEAM 最新ニュース

Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced...

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb...

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

All Seven Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Post-BEAM-101 Treatment Initial Safety...

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
1-3.49-12.28440689928.4129.1124.180577573626.18530441CS
4-0.66-2.5801407349525.583124.1805119343727.88213771CS
121.878.1127982646423.0532.2921.135116451125.91818898CS
262.028.8209606986922.934.0921.135104389126.09990825CS
52-2.03-7.5324675324726.9549.520.84120858227.45220264CS
156-54.83-68.752351097279.7582.6216.95111040736.08946655CS
2605.7329.859301719619.19138.52191394025846.00182845CS

BEAM - Frequently Asked Questions (FAQ)

What is the current Beam Therapeutics share price?
The current share price of Beam Therapeutics is US$ 24.92
How many Beam Therapeutics shares are in issue?
Beam Therapeutics has 82,805,627 shares in issue
What is the market cap of Beam Therapeutics?
The market capitalisation of Beam Therapeutics is USD 2.05B
What is the 1 year trading range for Beam Therapeutics share price?
Beam Therapeutics has traded in the range of US$ 20.84 to US$ 49.50 during the past year
What is the PE ratio of Beam Therapeutics?
The price to earnings ratio of Beam Therapeutics is -15.5
What is the cash to sales ratio of Beam Therapeutics?
The cash to sales ratio of Beam Therapeutics is 5.44
What is the reporting currency for Beam Therapeutics?
Beam Therapeutics reports financial results in USD
What is the latest annual turnover for Beam Therapeutics?
The latest annual turnover of Beam Therapeutics is USD 377.71M
What is the latest annual profit for Beam Therapeutics?
The latest annual profit of Beam Therapeutics is USD -132.53M
What is the registered address of Beam Therapeutics?
The registered address for Beam Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Beam Therapeutics website address?
The website address for Beam Therapeutics is www.beamtx.com
Which industry sector does Beam Therapeutics operate in?
Beam Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
ONCBeiGene Ltd
 183.98
(730.61%)
24.81k
RAINRain Enhancement Technologies Holdco Inc
 5.50
(354.55%)
25.35k
NITON2OFF Inc
US$ 0.782
(215.32%)
325.99M
CTCXCarmell Corporation
US$ 0.7563
(170.98%)
207.05M
CGBSCrown LNG Holdings Ltd
US$ 0.9458
(136.39%)
233.12M
NMRANeumora Therapeutics Inc
US$ 2.0301
(-80.85%)
22.47M
SISIShineco Inc
US$ 2.25
(-50.33%)
668.33k
BDMDBaird Medical Investment Holdings Ltd
US$ 5.0194
(-33.96%)
2.83M
SIDUSidus Space Inc
US$ 3.47
(-29.18%)
7.28M
NEHCNew Era Helium Inc
US$ 4.2791
(-28.68%)
888.22k
NITON2OFF Inc
US$ 0.798
(221.77%)
326.27M
CGBSCrown LNG Holdings Ltd
US$ 0.9459
(136.42%)
233.14M
CTCXCarmell Corporation
US$ 0.7568
(171.16%)
207.05M
XTIAXTI Aerospace Inc
US$ 0.04115
(-4.30%)
126.1M
SVMHSRIVARU Holding Ltd
US$ 0.0481
(14.25%)
117.31M

BEAM Discussion

投稿を表示

最近閲覧した銘柄

Delayed Upgrade Clock